Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Inclusion Criteria:

• Male or female ≥18 years or ≤80 years of age at signing of informed consent.

• Fasting LDL-C local lab value at the Screening Visit of either i) ≥100 mg/dL (2.6mmol/L) if on statin therapy but not on a maximally tolerated statin therapy; ii) ≥150 mg/dL (3.9mmol/L) if statin naive and without documented statin intolerance; oriii) ≥55 mg/dL (1.4 mmol/L) if on a stable (≥4 weeks) dose of maximally toleratedstatin therapy or if statin intolerant.

• Fasting LDL-C local lab value ≥55 mg/dL (1.4 mmol/L) at the assessment performedduring the Statin Optimization Period 3 Visit for participants going through theStatin Optimization Period.

• Participants having NOCAD without previous cardiovascular events: NOCAD is definedas:.

1. Participant with CT-adapted Leaman score >5. and a diameter stenosis <50% or

2. Participants with a CT-adapted Leaman score >5, a diameter stenosis ≥50% butwith FFRCT ≥0.76.

• A standard of care CCTA may serve as the study baseline CCTA scan if it is performedwithin 3 months prior to the participant's Screening Visit and meets the inclusioncriteria of FFRct >0.8 and CT-adapted Leaman score >5, which will be assessed by theImaging Core Lab.

• At the Baseline Visit, participants must be on a stable (≥4 weeks) dose of maximallytolerated statin therapy. Participants not on maximally tolerated statin therapy andwho do not have documented statin intolerance can be screened but must enter thestudy via a Statin Optimization Period.

• Fasting LDL-C lab value ≥55 mg/dL (1.4 mmol/L) at the Baseline Visit, measured atthe central laboratory. If the Baseline and Screening Visits occur on the same day,then the LDL-C assessment will be assessed on the central laboratory sample. If aparticipant qualifies at Screening but the fasting central lab LDL-C value at theBaseline visit does not meet eligibility, then eligibility will be determined basedon the central lab result.

• Fasting triglycerides value <400 mg/dL (4.52 mmol/L) based on the local lab resultsat the Screening visit and on the central lab results at the CCTA visit.

Exclusion Criteria:

• Previous cardiovascular events history including myocardial infarction (MI), orprior coronary revascularization [percutaneous coronary intervention (PCI) orcoronary artery bypass graft (CABG)].

• Planned revascularization (PCI) or (CABG).

• Previous cerebrovascular events including:

• Prior ischemic stroke thought not to be caused by atrial fibrillation, valvularheart disease or mural thrombus.

• History of prior percutaneous or surgical carotid artery revascularization.

• History of Peripheral Artery Disease (PAD):

• Prior documentation of a resting ankle-brachial index <0.85.

• History of prior percutaneous or surgical revascularization of an iliac,femoral, or popliteal artery.

• Prior non-traumatic amputation of a lower extremity due to peripheral arterydisease.

• Cardiac disorders, including any of the following:

• Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia,atrial fibrillation) within 3 months prior to randomization that is notcontrolled by medication or via ablation at the time of the Screening Visit.

• Complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third-degree AV block) prior torandomization.

• Contraindication for CCTA (e.g., allergic reactions to the contrast dye) or CCTA notmeeting entry standards after two attempts during the Baseline CCTA Visit asassessed by the Imaging Core Lab.

• Pacemaker or implantable cardioverter-defibrillator (ICD) in situ.

• Systolic Left Ventricle Ejection Fraction <30% at the Screening Visit.

• Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolicblood pressure >110 mmHg prior to randomization (assessed at the Screening Visit)despite antihypertensive therapy.

• Heart failure New York Heart Association (NYHA) class III or class IV at theScreening Visit.

• Renal insufficiency (eGFR <30 mL/min/1.73m2) as measured by the Modification of Dietin Renal Disease (MDRD) formula at the Screening Visit and at the StatinOptimization 3 Visit.

• Active liver disease defined as any known current infectious, neoplastic, ormetabolic pathology of the liver at the Screening Visit.

• Local creatine kinase (CK) values of either, unless a more stringent threshold ismandated by a local regulatory authority

• Local CK values ≥5x ULN at the Statin Optimization 3 Visit unless a more stringentthreshold is mandated by a local regulatory authority

• Participant with myopathy at the Statin Optimization 3 Visit.